TVGN TEVOGEN BIO HOLDINGS INC

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

WARREN, N.J., April 14, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announces CEO Dr. Ryan Saadi, MD, MPH, will participate in . Dr. Saadi will be featured on the panel discussion titled Paths to Liquidity: Strategies for Adapting to a Volatile Market, moderated by David C Schwartz, Partner at . Along with Dr. Ryan Saadi, the panel will also include commentary from Matt Vamvakis, MBA, Managing Director, , Amanda Laskey, Life Sciences Senior Analyst, , and Kee Colon, MBA, Managing Director, .

The conference, held on May 13, 2025, at The Liberty Science Center in Jersey City, NJ, historically brings together investors, BD professionals, academic collaborators, innovators and biopharmaceutical industry executives to foster strategic partnerships, drive funding, and accelerate collaboration, with the ultimate goal of advancing medical innovation and transforming the future of healthcare.

“I look forward to joining in the upcoming panel discussion hosted by BioNJ,” said Dr. Saadi. “This is a critical moment for the biotechnology industry to address market volatility and its potential impact on patient outcomes. The topic is closely aligned with Tevogen Bio’s mission to advance accessibility and affordability to lifesaving treatments.”

“The conference’s action-packed agenda, featuring 1:1 partnering sessions, company pitch presentations, the Industry Connections Desk, exhibits, extensive networking opportunities and engaging plenary discussions, was thoughtfully designed to provide entrepreneurs with a dynamic environment geared toward growth and collaboration,” said BioNJ President and CEO Debbie Hart. “With that in mind, we’re thrilled to welcome Dr. Saadi and his fellow panelists to share their invaluable insights during “Paths to Liquidity: Strategies for Adapting to a Volatile Market”. Attendees are certain to walk away with meaningful, actionable takeaways.”

Contacts

Tevogen Bio Communications

T: 1 877 TEVOGEN, Ext 701



EN
14/04/2025

Underlying

TVGNTEVOGEN BIO HOLDINGS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TEVOGEN BIO HOLDINGS INC

 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen Updates on Development of EBV-Specific T Cell Therapy with Sup...

Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery WARREN, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ) today provided an update on its ongoing development of a cytotoxic T lymphocyte (CTL) therapy targeting Epstein-Barr virus (EBV)-associated lymphomas. Computer-based selection of EBV peptides is currently underway as part of Tevogen’s preparation for a potential clinical trial using EBV-specific CTLs manufactured using the Company’s proprietary ExacTcell™ technology. ExacTcell...

June 18, 2025 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimil...

Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives R&D and cross-functional operations will be centralized in a single location to enhance collaboration and operational efficiency.Tevogen.AI, strengthened by its partnership with Microsoft, continues to expand. An update on AI and other Company assets, to have a market value of $10 billion, is forthcoming.Shareholders will soon receive an update on Tevogen’s goal of finalizing in-house manufacturing capabilities, which are expected to support projected cumulative revenues of $10–14 billion for Tevogen Onco...

June 9, 2025 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Pr...

Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships WARREN, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today provided stockholders with a detailed overview of its artificial intelligence initiative, Tevogen.AI™. Tevogen.AI™ aims to integrate advanced machine learning and predictive modeling into Tevogen Bio’s proprietary ExacTcell™ technology to significantly enhance its target identification and pre-clinical processes, thereby strengthening ...

May 30, 2025 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patient...

Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow WARREN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced a planned expansion of TVGN 489’s target population to include patients 65 and older. , the top-line revenue forecast for the specialty care pipeline was projected at nearly $1 billion in its launch year, with a cumulative five-year estimate ranging between $18 billion and $22 billion. This anticipated expan...

May 23, 2025 1 EN
 PRESS RELEASE
Free
TVGN TEVOGEN BIO HOL...

Tevogen to Update on Robust Portfolio Assets, Business Expansion, Part...

Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting WARREN, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: ), today announced that it will provide several updates to stockholders in advance of the Company’s upcoming Annual Meeting of Stockholders scheduled for June 23, 2025. These updates will provide content regarding the Company’s innovative business model and strategic growth initiatives, which management ...

May 22, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch